Cumberland Pharmaceuticals opened lower at $6.06, compared with its previous close of $6.12. In the last trading session, the stock traded between $6.06 and $7.39. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Cumberland Pharmaceuticals is now worth
$ 246.80
Giving a profit of
$ 146.80 (146.80%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
+$0.52 (+8.48%)
Day High
$7.39
Day Low
$6.06
Day Open
$6.06
Prev Close
$6.12
Volume
3,77,401
1W Return
48.36%
1M Return
-5.48%
3M Return
-16.49%
6M Return
45.27%
1Y Return
231.95%
Fundamentals
Market Cap ($ Mn)
99
PE Ratio
-
PB Ratio
7.27
PEG Ratio
-
ROE
-10.98%
ROCE
-6.52%
EPS (TTM)
$-0.29
Investment Returns
1 Week
48.36%
1 Month
-5.48%
3 Months
-16.49%
6 Months
45.27%
9 Months
71.55%
Financials
Quarterly
All values in $ Mn
11.7
Mar 25
10.8
Jun 25
8.3
Sep 25
13.7
Dec 25
9.1
Mar 26
0.2
Jun 26
Updates
11Nov
Cumberland Pharmaceuticals Q3FY26 Results: Net income $77.8M, declares $1.50 dividend
Net income reached $77.8 million in Q3FY26, driven by the gain from the Apotex Health transaction. Total assets grew to $114 million and cash holdings rose to $80.6 million with zero debt. Board declared a special dividend of $1.50 per share totaling $22 million. Strategy shifted to rare disease development with ifetroban NDA submission planned for DMD.
2 days ago
6Nov
Levi & Korsinsky joins probe into Cumberland Pharma trial disclosures
Levi & Korsinsky notified investors of a pending investigation into Cumberland Pharmaceuticals. Shares fell almost 48.8% on October 26, 2026, after Phase 2a trial failure announcement. Investigation alleges false or misleading statements regarding ifetroban efficacy. Eligibility for claims depends on purchase dates and documented losses, not current holdings.
7 days ago
29Jul
Cumberland Pharmaceuticals Q2 Results: Company update and earnings call set for Aug 4
Cumberland Pharmaceuticals Inc. will release Q2 2026 financial results and a company update on August 4, 2026. A conference call is scheduled for 4:30 p.m. ET, with a replay available for one year. The company is advancing Phase 2 trials for ifetroban in rare diseases including Duchenne Muscular Dystrophy and Systemic Sclerosis.
3mo ago
13Jul
Cumberland Pharmaceuticals declares $1.50 special dividend
Cumberland Pharmaceuticals Inc. declared a $1.50 per share special dividend, payable July 31, 2026, to shareholders of record on July 10, 2026.
4mo ago
26Jun
Cumberland FIGHT DMD trial shows 30% MYL3 cut
Cumberland Pharmaceuticals Inc. presented 36-month data from its Phase 2 FIGHT DMD trial, showing ifetroban significantly reduced heart damage biomarkers MYL3 and MYOD1 by 30% and 50%, respectively, while increasing cardioprotective proteins FGF16 and TSPAN7. The therapy maintained a favorable safety profile with no treatment-related serious adverse events, reinforcing its potential to treat DMD-associated cardiomyopathy.
